Physician
Hematology
Dr. David M. Waterhouse, MD
|
|
Give Review
David M. Waterhouse, MD practices Hematology. He graduated from University of Massachusetts Medical School. University of Massachusetts Medical School has a rank of 49 in research and a 12 in primary care He received 2 awards: "Meaningful Use Stage 1 Certification" and "Top MD". Dr. David M. Waterhouse is also published. He has 34 publications published. The lastest publication: "Cancer incidence in the rural community of Tecumseh, Michigan: a pattern of increased lymphopoietic neoplasms.' He is registered with Medicare.
Publications
- A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases ...
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizu...
- Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast Cancer.
- High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium.
- Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Ph...
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic Carcinoma of the pancreas: A Sarah Cannon Research Institute phase II...
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast Cancer patients who have received no more than one prio...
- A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced N...
- Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer.
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer.
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75.
- Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung Cancer: results from the SALUTE trial.
- Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplati...
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal Cancer.
- Phase II trial of bevacizumab and everolimus in patients with advanced renal cell Carcinoma.
- A small tolerance for catheter displacement in high-dose rate proState brachytherapy is necessary and feasible.
- Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with Carcinoma of unknown primary site.
- Pemetrexed plus cetuximab in patients with recurrent non-small cell lung Cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
- Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast Cancer.
- Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung Cancer.
- Treatment of advanced renal cell Carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate Cancer: a report from the ...
- Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung Cancer.
- Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic Cancer: results of a phase II randomized, doub...
- Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung Cancer.
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic Cancer.
- A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast Cancer.
- Cancer incidence in the rural community of Tecumseh, Michigan: a pattern of increased lymphopoietic neoplasms.
- Attitudes and behaviors on physician-assisted death: a study of Michigan oncologists.
- Combined carboplatin and cisplatin. Limited prospects for dose intensification.
- Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.
- Smoking in young men with testicular Cancer.
Schools
University of Massachusetts Worcester Campus
University Mass Med Center
University Mich Med Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Top MD
Education
-
University of Michigan Hospitals and Health Centers -
University of Massachusetts -
University of Massachusetts Medical School
Hospital
-
Christ Hospital
Drug Facts
| NPI NUMBER | 1578557864 | |
| NPPES Provider LastName | WATERHOUSE | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 452425621 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1127.0 | |
| Distinct Opioid Count | 7.0 | |
| Opioid Claim Count | 246.0 | |
| Percent Opioid Claims | 21.83 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578557864 |
| Last Name Of The Provider | WATERHOUSE |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Edward J. Crane, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David L. Kirlin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia C. Chua, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karyn M. Dyehouse, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca G. Bechhold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary E. McCullough, MD |